Patient support programs: A significant source of real-world data
By Innomar Strategies
Patient support programs are an increasingly important source of data — demonstrating the value of therapies for key stakeholders. Hear from Belinda Yap, Director, Health Economics & Outcomes Research (HEOR), about the many opportunities you’ll have to collect this type of data and why it’s important to start early.
The contents of this piece contain marketing statements and do not include business or legal advice.
Transcript of 'Patient support programs: A significant source of real-world data'
How can PSPs be leveraged for RWE?
Canada's well-established patient support program, or PSP, infrastructure offers a unique opportunity with patient consent to leverage the PSP as a platform for real-world data collection. Upon patient consent and with the support from the manufacturers, the real-world evidence, or RWE, that's generated through the PSP could help demonstrate the value of therapies to key stakeholders, for example, prescribers, KOLs, and payers. This applies to the efficacy, safety, utilization, and adherence in actual practice, thereby supporting approval and funding needs, facilitating decision-making, and enhancing patient care.What are the benefits of using PSPs as a source of RWE?
PSP as a source of real-world data has many distinctive benefits. Firstly, there's the opportunity for comprehensive data collection with pan-Canadian representation. This is especially the case for therapies in the rare disease space and specialty medications, as most, if not all, patients are enrolled in PSP. And secondly, there are numerous opportunities to collect information due to the high touchpoints with patients during their journey within the PSP.What are some considerations when planning a PSP?
So the real-world data collected through PSP can serve as a standalone patient registry for patients receiving treatments in Canada. For PSPs part of an organization that adopts an integrated model for patient services, there is also the ability to leverage various other data sets within that organization, such as pharmacy, wholesale and distribution, as well as opportunity to integrate with external data sources through digital platforms, or linkage to third-party administrative databases, and thereby enabling data integration across multiple data sets. We therefore recommend to manufacturers planning on operationalizing their PSP in Canada to start early, preferably at the design phase, to proactively identify and incorporate data collection needs into the PSP in order to maximize data collection opportunities for RWE.
